Congress Materials – American Psychiatric Association Annual Meeting (APA 2026)
2026 American Psychiatric Association Annual Meeting | May 16-20 | San Francisco, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Long-Term Safety and Efficacy of Esketamine Nasal Spray Among Latino and Hispanic Adults With Treatment-Resistant Depression in the SUSTAIN-3 Study
Lisa Harding, Ibrahim Turkoz, Larry Martinez, Clairissa Cruz
Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial
Suresh Durgam, Raffaele Migliore, Yifan Mo, Hassan Lakkis, Susan G. Kornstein
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.